GlassScriptPhysician profile
Mark W Sawka
NPI 1609873496
$2,219.87
in general payments reported to CMS, 2019-2025
25 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $148 · 2021: $569 · 2022: $282 · 2023: $233 · 2024: $392 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $482.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.67 | 2019-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $361.48 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $187.21 | 2019-2023 | |
| Pfizer INC. | $179.24 | 2019-2025 | |
| Amarin Pharma, INC. | $87.93 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $76.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.92 | 2024-2025 | |
| Abbvie INC. | $52.81 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.67 | 2022 | |
| Glaxosmithkline, LLC. | $43.42 | 2022-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.06 | 2019 | |
| Sanofi Pasteur INC. | $28.91 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $28.79 | 2024 | Voquezna |
| Dexcom, INC. | $22.48 | 2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.42 | 2025 | Veozah |
| Inogen, INC. | $17.38 | 2022 | |
| Merck Sharp & Dohme LLC | $17.10 | 2021 | |
| Abbott Laboratories | $13.27 | 2022 | |
| Ibsa Pharma INC. | $13.07 | 2020 | |
| Allergan, INC. | $12.29 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.78 | 2021 | |
| Preventice Services, LLC | $11.73 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.27 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sawka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.